Routine use of concurrent fluoroscopic imaging during superficial endovenous interventions: A position statement of the International Union of Phlebology (UIP), the Australasian College of Phlebology (ACP), the Australia and New Zealand Society for Vascular Surgery (ANZSVS), the American Venous Forum (AVF), the American Vein and Lymphatic Society (AVLS), the European College of Phlebology (ECoP) and the Interventional Radiology Society of Australasia (IRSA).
Journal
Journal of vascular surgery. Venous and lymphatic disorders
ISSN: 2213-3348
Titre abrégé: J Vasc Surg Venous Lymphat Disord
Pays: United States
ID NLM: 101607771
Informations de publication
Date de publication:
11 2022
11 2022
Historique:
received:
22
06
2022
accepted:
11
07
2022
pubmed:
16
8
2022
medline:
19
10
2022
entrez:
15
8
2022
Statut:
ppublish
Résumé
International evidence-based guidelines recommend preoperative duplex ultrasound mapping in the assessment of chronic venous disease, and concurrent ultrasound imaging to guide superficial endovenous interventions such as endovenous laser ablation, radiofrequency ablation, cyanoacrylate adhesive closure, and sclerotherapy (ultrasound-guided sclerotherapy). Other imaging modalities such as venography, alone or in combination with computed tomography scan or magnetic resonance imaging, may be included in the preoperative assessment of a small and select group of patients to exclude central venous obstruction, certain deep venous pathologies, pelvic origin extrapelvic varices, and complex vascular malformations. The signatory scientific and medical societies recommend against the routine use of fluoroscopy and other radiation-based imaging in the investigation and treatment of superficial venous disease.
Identifiants
pubmed: 35970306
pii: S2213-333X(22)00350-X
doi: 10.1016/j.jvsv.2022.07.009
pii:
doi:
Substances chimiques
Cyanoacrylates
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1198-1200Informations de copyright
Copyright © 2022. Published by Elsevier Inc.